In Berlin wird XENOVA GROUP verschenkt !! Kurs 4,50 Euro in Berlin ! Schlußkurs nachbörslich 6,5 $ - 500 Beiträge pro Seite

[oberfuchs]

Urteil: Kaufen!!

Gruß oberfuchs

[dexter]

kennst du die gründe !??

danke + grüße dx

[Schnelle]

Kann mir hier jemand erklären, warum adr steigt und unserer nicht??Glaube, daß hat gar keinen Einfluß, daß die nachbörslich gestiegen sind!Andere Aktie

[Steffo]

Kurd wird in London gemacht, Xenova ist ein englisches Unternehmen!!
In US und D werden nur ads gehandelt, warum die Amis so rumspinen weiß ich auch nicht, konnte keine News finden

[dexter]

hab mich mal schlau gemacht: alles bullshit, da wollte mal einer so schlau sein wie ein fuchs. die aktie von der hier geredet wird ist

[/b]FALSCH

vielmehr geht es um 890282 die entsprechend nicht in london gehandelt wird.


leute,leute,leute

fuchs in die ecke mit dir

[oberfuchs]

Hallo zusammen
Keine Panik!
890281 und 890282 ist die gleiche Firma.
Dieser Kursabschlag ist nicht gerechfertigt.

Kurs in Berlin schon bei 5 Euro und das bei Rekordumsätzen.
Vorbörslich in America 6 $ !!!

Gruß oberfuchs aus der Ecke

[oberfuchs]

Hallo
Kurs bei Eröffnung in USA 6,25 $ !!

Gruß oberfuchs

[star2000]

Hallo

Heute über 7$ in USA geschlossen.
Toller Gewinn oder?

cu star2000

[cikei]

Hallo Leute,
bin gestern bei Xenova eingestiegen, würde jedoch gerne wissen, was ihr denn von der Firma haltet. Welche Kursziele exitieren kurzfristig?
Ciao

[Alex12345]

Meiner Meinung nach fallen die 10 E noch diese Woche und wer weiß, wie es dann weiter geht. Meiner Meinung nach ist der Weg nach oben frei.
Mich würden allerdings auch noch andere Meinungen zu diesem Thema (KZ) interessieren.

Cu Alex12345

[Alex12345]

NAS : 7,34 $

Na dann sehen wir Montag wohl auf jeden Fall die 7 E.

[Ben Lechef]

Woger kriegt ihr Nach/Vorbörsichliche Informationen, was agen sie über den weiteren Kursverlauf konkret aus?

[oberfuchs]

Hallo Alex

Ich hoffe auch das XENOVA am Montag die 7 Euro sieht.
Es wäre durchaus möglich das sie in Deutschland aber wieder unter eigentlichen Wert verkauft wird.

Kursziel 10 Euro sind nächste Woche locker drin.


Gruß oberfuchs

[Plotin]

Ich bin auf der Suche nach versteckten Perlen mit
Langzeitperspektive auf Xenova gestoßen, weiß aber recht wenig
über die AG. Gibt`s Analysten-Statements? Worauf stützen sich die Kursziele?

[DEHO 2000]

Xenova ist von amerikanischen Biotechfonds entdeckt worden;
das dürfte dem Kurs nachhaltig gut tun.

Quelle: www.nasdaq.com; Symbol XNVA -> company news


UK biotechs rise after investor meet, U.S. =2

Cantab`s American Depository Receipts have risen from around $10 on February 11 to close at $30-1/2 on Thursday. During the
same period its London-listed shares have risen from 218 pence to 730 pence.

"There was some switching yesterday in the U.S. from big to small and medium-sized biotech firms and both Cantab and Xenova
have been beneficiaries," said one analyst.

Several fund managers in the U.S. have been picking up select biotech stocks in Europe which have been found short of U.S.
valuations despite being involved in similiar therapeutic areas.

Its been a similiar story with Xenova, <XNVA.O> whose ADRs were valued at around a dollar on February 7 but closed on
Thursday at over $5.

Xenova is also expected to reveal further progress on its cancer-based products on Tuesday when it announces its annual results.

Among the companies that presented at the Charterhouse meeting on Thursday was French genomics company Genset SA
<GENX.LN>, up three euros to 195 euros on the Nouveau Marche stock exchange. Cerep <CERF.LN>, a combinatorial chemistry
company, shares rose three euros to 106, gene therapy company Transgene <TRGNY.O> <TRNG.LN>, gained 50 cents to 95.50
euros and Nicox <NCOX.LN> rose 7.45 euros to 90.95. All three are based in France.

((Arindam Nag, London newsroom [phone], fax [phone], [e-mail]))

REUTERS

Rtr 06:42 03-03-00


Fette Gewinne
DEHO

[oberfuchs]

up

[Der Lange]

ich habe auch noch was! Soll es da etwa am Dienstag einen Schub geben? Gönnen würde ich mir es ja!:


Search Company Ticker Keyword People News IPOs Quotes All Directories for
More searches
and Power Tool




To print this story

UK biotechs rise after investor meet, U.S. buying
Reuters Story - March 03, 2000 06:27




Copyright 2000 Reuters Limited. All rights reserved. Republication or
redistribution of Reuters content is expressly prohibited without the prior
written consent of Reuters. Reuters shall not be liable for any errors or
delays in the content, or for any actions taken in reliance thereon.
LONDON, March 3 (Reuters) - Shares in three British biotechnology companies
-- Cambridge Antibody Plc , Oxford Glycosciences and Phytopharm -- rose on
Friday following a bullish presentation to a group of investors on Thursday.

The three companies -- and four from Europe -- made presentations at a
meeting organised by Charterhouse Securities.

CAT, which earlier this week unveiled a blockbuster deal with genomics group
Human Genome Sciences Inc, was up 137-1/2 pence or 3.6 percent to 40.12-1/2
pounds at 1050 GMT.

Oxford Glycosciences shares were up 85 pence or 3.21 percent to 27.32-1/2
pounds while Phytopharm -- a company specialising in making medicines out of
plant extracts -- was the biggest winner, adding 58-1/2 pence or 12.72
percent at 518-1/2p.

Analysts also said that shares in Xenova Group Plc , a cancer company and
vaccine maker Cantab were up following strong buying interest from the United
States. Both of them have listings on Nasdaq.

Cantab`s American Depository Receipts have risen from around $10 on February
11 to close at $30-1/2 on Thursday. During the same period its London-listed
shares have risen from 218 pence to 730 pence.

"There was some switching yesterday in the U.S. from big to small and
medium-sized biotech firms and both Cantab and Xenova have been
beneficiaries," said one analyst.

Several fund managers in the U.S. have been picking up select biotech stocks
in Europe which have been found short of U.S. valuations despite being
involved in similiar therapeutic areas.

Its been a similiar story with Xenova, whose ADRs were valued at around a
dollar on February 7 but closed on Thursday at over $5.

Xenova is also expected to reveal further progress on its cancer-based
products on Tuesday when it announces its annual results.

Among the companies that presented at the Charterhouse meeting on Thursday
was French genomics company Genset SA , up three euros to 195 euros on the
Nouveau Marche stock exchange. Cerep , a combinatorial chemistry company,
shares rose three euros to 106, gene therapy company Transgene , gained 50
cents to 95.50 euros and Nicox rose 7.45 euros to 90.95.

All three are based in France

[PeteInvests]

Guten Morgen,
wird das nun zur Regel, daß man bei Xenova
den ganzen Vormittag lang noch Arbitrage zum US-Kurs
betreiben kann ?
Mir soll`s recht sein.
Zur Info: Schluß an der NASDAQ 7.34 $.
Wir stehen seit kurz noch 9 Uhr immer noch bei 6.50 E.
hat es außer mir eigentlich keiner mehr nötig, sicheres Geld
zu verdienen ?
Nun aber mal los...

Viel Erfolg, PI

[oberfuchs]

Hallo
Heute sind die ersten 100% Gewinn erreicht. Die Party geht weiter!

Gruß oberfuchs

[bioscope]

Xenova Group plc Preliminary Results for the Year Ended 31 December 1999 And Successful Completion Phase IIa Study XR9576/Paclitaxel - to Enter Pivotal Phase III Studies

SLOUGH, England, Mar 7, 2000 /PRNewswire via COMTEX/ -- Xenova Group plc
(Nasdaq: XNVA; London: XEN) today announces its results for the year to 31
December 1999.


XR9576 To Enter Phase III Studies
-- XR9576 successfully completes Phase IIa PK study with paclitaxel
(taxol); to enter pivotal Phase III studies in Q4 2000

Operational Highlights
-- Multi-drug resistance modulator XR9576 in Phase IIa studies with three
commercially important cytotoxics
-- Cytotoxic XR5000 enters Phase II studies in four tumour types
-- Sale of Xenova Discovery business provides 1m pounds sterling (pounds)
cash and retained rights
-- Sale of MetaXen assets, intellectual property rights retained
-- Next generation cytotoxic XR11576 enters preclinical development
-- Revised Scientific Advisory Board and appointment of new Research and
Development Director

Financial Highlights
-- Placing plus exercise of Warrants raises 8.4m pounds (net)
-- Asset sales reduce cash burn with consideration received of 4.1m
pounds

"The announcement today that XR9576 will enter Phase III pivotal studies is a
significant development and indicates the strength of the Group`s oncology
focus. We are encouraged by the potential of XR9576 in eliminating problems of
drug resistance in the treatment of cancer," said David Oxlade, Chief Executive
Officer of Xenova Group plc.

He continued: "On a broader note, 1999 was a year of transition for Xenova. We
entered 2000 with our two lead drug candidates near to completion of Phase II
trials and a broader and stronger preclinical pipeline. The Xenova Discovery and
MetaXen disposals have allowed us to focus the Group on higher value added
proprietary drug discovery and development and to substantially reduce cash
burn."

Chief Executive`s Review

Throughout 1999 Xenova successfully implemented the strategic objectives first
outlined to shareholders in mid 1998. With its focus on the discovery,
evaluation and development of novel drugs, primarily for cancer, the Directors
believe the Group to be well positioned to take advantage of future
opportunities.

The Group`s underlying strategy is to further develop its growing product
pipeline through active in-licensing and academic collaborations; to manage risk
through commercial partnering at the appropriate or optimal time for each
project; and to generate revenues through commercial partnering, with retained
market rights and royalties. The Group currently has two oncology-related
products in a total of 7 Phase II clinical trials and a substantial preclinical
portfolio. Completion of all Phase II trials for both products is anticipated in
2000.

The Group`s financial position was strengthened by a June 1999 placing, which
raised 1.8m pounds net of expenses, and the exercise of warrants issued in
connection with the September 1998 Placing and Open Offer. Exercise of warrants
realised a total of 6.6m pounds net. The sales of the Xenova Discovery and
MetaXen businesses realised a gain and have reduced the rate of cash burn. In
both cases, Xenova has retained valuable rights to intellectual property and to
certain potential future revenue flows arising from the businesses prior to the
disposals. It was today announced that a non-exclusive licence has been granted
to Exelixis Pharmaceuticals Inc to use certain software and databases developed
by MetaXen.

Product Development

The company commenced a total of 7 Phase II clinical trials in early 1999 with
its two most advanced drugs, XR9576 and XR5000.

XR9576 -- The Group announced today that the Phase IIa study involving XR9576
and paclitaxel (taxol) (one of the world`s largest selling cytotoxic drugs) in
ovarian cancer patients has been completed and that the positive interim
pharmacokinetic results have been confirmed in the full data set from the 12
patients in the study. The Directors expect that XR9576 will enter pivotal Phase
III studies in late 2000.

XR9576 is a compound which is being developed to restore the sensitivity of
multi-drug resistant cancer cells to specific anti-cancer drugs, by modulating
the action of the P-glycoprotein (P-gp) pump. Up to 90 per cent of cancer
patients are estimated to develop resistance to current anti-cancer drugs and
P-gp related multi-drug resistance is the most common form of this phenomenon.
The Directors are not aware of any approved drugs which are currently marketed
as P-gp modulators.

The Phase IIa iv programme for XR9576, which is being carried out at five
centres in both the US and Europe, is studying the effects of XR9576 in
combination with a variety of approved commercially and therapeutically
important cytotoxic drugs namely doxorubicin, paclitaxel and vinorelbine. These
drugs are approved for use in a number of tumour types such as breast and
ovarian. The purpose of the studies is to assess the degree of drug interaction,
if any, between XR9576 and the cytotoxic drug.

The Phase IIa study involving XR9576 and paclitaxel in 12 ovarian patients,
which has now been completed, confirmed the positive interim pharmacokinetic
results for this trial, which were announced in November 1999. The study shows
that paclitaxel can be administered at the full normal dose with XR9576 as a
single administration. The study was carried out at The Royal Surrey County
Hospital, Guildford, UK, in patients with second line ovarian cancer recurring
more than 6 months after previous treatment, who had previously been treated
with a variety of cytotoxic drugs, including paclitaxel and platinum drugs. A
number of patients in the study are continuing on therapy with XR9576 and
paclitaxel and these patients are expected to complete their treatment by mid
2000. The outcome of the study indicates that XR9576 was well tolerated when
administered with paclitaxel, and caused no significant drug interaction.
Patients received paclitaxel at the standard dose of 175mg/m squared, with a
single intravenous XR9576 dose of 150mg 2 hours prior to administration of
paclitaxel.

Investigational new drug (IND) approval was received in November 1999 and US
trials, in which XR9576 is being co-administered in conjunction with
vinorelbine, in up to 30 patients, are being carried out in conjunction with the
National Cancer Institute (NCI). The first patients have entered combination
treatment. Results from this study are expected to be available by mid 2000.

Recruitment is well advanced for the doxorubicin/XR9576 Phase IIa trial. The PK
data from this study are expected to be available shortly. The 12 patients in
this study should be able to continue for up to 6 cycles of treatment.

Phase I study results for the intravenous and oral administration of XR9576 were
presented at the May 1999 meeting of the American Society of Clinical
Oncologists, and demonstrated that XR9576, when given by either route, was well
tolerated at all doses and gave virtually complete inhibition of P-gp, as
measured in CD56+ cells. Data from these studies were used to select the dose
for the Phase II studies as a once-per-day treatment.

XR5000 -- Phase II clinical trials are also underway for XR5000, a topoisomerase
I and II inhibitor, at a number of European centres.

XR5000 is being developed as a novel cytotoxic for the treatment of common solid
tumours. It has the potential to inhibit the action of both topoisomerases I and
II, enzymes which are critically involved in the duplication of DNA during the
process of cell growth and division. In preclinical studies XR5000 has been
shown not to be susceptible to the main multi-drug resistance mechanisms. It has
also been shown to cross the blood-brain barrier, which the Directors believe
gives it a unique profile of action.

The Phase II open label efficacy studies are being conducted on patients
recruited into the pan-European, multi-centre trial by the European Organisation
for the Research and Treatment of Cancer (EORTC). Up to 25 patients may be
treated in each study, which is underway in each of four different tumour types
-- ovarian, colorectal, non-small cell lung and glioblastoma. Patients enrolled
in these studies may take multiple doses of XR5000 for up to six cycles of
therapy. The use of an ambulatory pump for drug delivery allows patients to be
treated on an out patient basis. The Directors expect preliminary data from
these studies to be available by mid 2000.

Pre-Clinical Development

The adoption of a novel, orally active, next generation cytotoxic topoisomerase
I and II inhibitor, XR11576, as a preclinical development candidate was
announced in November 1999. XR11576 is designed to have a different chemical
structure to XR5000, with an improvement in its clinical profile versus other
drugs, while retaining the benefits XR5000 potentially provides. The candidate
is currently undergoing full preclinical safety evaluation studies, and if these
evaluation studies are successfully completed, the Directors expect clinical
studies to begin before the end of 2000.

Research in the Plasminogen Activator Inhibitor-1 (PAI-1) collaboration with
Lilly, which targets the development of a new class of antithrombotic drugs
suitable for chronic use, is being conducted jointly by Xenova and Lilly.
Certain research work in connection with this collaboration was previously
carried out by MetaXen. As part of the transfer of staff and assets of MetaXen
to Exelixis in 1999, Xenova has retained all rights to milestones and royalties
due under this collaboration.

Preclinical research is also continuing with the goal of identifying drug lead
candidates which address the roles of multi-drug resistance protein (mrp) in
cancer and in asthma, and the role of PAI-1 in metastatic cancer.

Proof of principle for the method of action of PAI-1 in cancer was presented by
Xenova at the July 1999 meeting of the British Association for Cancer Research.
Lilly has been granted an option to acquire exclusive rights to develop and
commercialise PAI-1 inhibitors in cancer.

In February 2000 Xenova announced the formation of a collaborative research
agreement for the discovery and development of novel classes of telomerase
inhibitors with Professor Robert Newbold and his team at The Institute of Cancer
Genomics and Pharmacogenomics, Brunel University, Uxbridge, UK.

Management

To reflect the company`s oncology focus, the structure of Xenova`s Scientific
Advisory Board (SAB) was amended in May 1999. The new SAB, led by Professor Stan
Kaye, Head of the Cancer Research Campaign Department of Medical Oncology at the
University of Glasgow, Scotland, is composed of a number of leading oncology
professionals -- Professor Paul Workman, Director of the Cancer Research
Campaign Centre for the Cancer Therapeutics Institute of Cancer Research,
London, Professor Herbie Newell, Director of Cancer Therapeutics at the Cancer
Research Unit, the University of Newcastle upon Tyne, Professor Mike Waterfield,
Director of Research at the Ludwig Institute for Cancer Research at University
College, London and Professor Adrian Harris, Director of the Imperial Cancer
Research Fund Molecular Oncology Laboratories and Director of the ICRF Medical
Oncology Unit in Oxford, England. Professor Harris is also a non-executive
director of Xenova Group plc. Stephen B Howell, Professor of Medicine at the
University of California, San Diego, joined Xenova`s SAB in January 2000.

Following the decision of Dr Paul Bevan to step down from his executive role,
Dr. John Waterfall was appointed as Xenova`s Research and Development Director.
Dr. Waterfall joined Xenova from Hoffmann-La Roche, Nutley, New Jersey, USA,
where he was Divisional Vice President, Global Project Management. Dr. Bevan
remains as a non-executive director of the Company. In May 1999 Dr. Michael
Moore, who was formerly head of Xenova Discovery, was appointed Chief Scientific
Officer with special responsibility for thekVe director of Xenova Group plc,
Mr. Peter Gillett, a partner at audit and financial services firm Ernst & Young,
was appointed as a non-executive director in February 2000. Peter Gillett
currently chairs Xenova`s Audit Committee.

Outlook

Xenova intends to continue to fulfil its strategic objectives through a strategy
which includes the continuing discovery and development of novel drugs of high
commercial potential, where the Group creates and owns the intellectual property
involved and retains commercialisation rights to this intellectual property.
Under this strategy, commercialisation of the products of the Group`s research
may occur through partnering with major pharmaceutical companies at the optimal
point, having regard to the level of scientific and commercial risk and return
for each individual project. This may result in the Group taking products
through to completion of Phase III clinical trials in its core cancer area, and
may result in earlier stage partnering for products for other indications.


Financial Summary

Operating Performance

Turnover for the year was 2.7m pounds ($4.3m) (1998: 4.9m pounds ($7.8m)).
Receipts of 2.3m pounds ($3.7m) under the PAI-1 agreement with Lilly represent
recovery of research expenditure. 1998 PAI-1 receipts of 4.1m pounds ($6.8m)
included milestone payments from Lilly of 1.3m pounds ($2.2m) as well as the
recovery of research expenditure. Turnover in the six months to 31 December 1999
was 0.9m pounds ($1.4m) (1998: 1.9m pounds ($3.1m)), with the decrease primarily
attributable to the transfer in-house to Lilly of work in connection with the
ongoing Xenova/Lilly strategic cardiovascular research and development
programme.

Operating costs declined to 13.6m pounds ($22.0m) (1998: 19.5m pounds ($31.4m))
and comprised 11.3m pounds ($18.2m) (1998: 16.5m pounds ($26.6m)) of research
and development costs and 2.3m pounds ($3.7m) (1998: 3.0m pounds ($4.8m)) of
administrative expenses. The reduction in operating costs reflects the fall in
the headcount at 31 December 1999 to 57 (1998: 123) following the disposal of
the non core businesses and disposal of surplus leasehold property in the US and
UK. Research and development costs for continuing operations increased to 7.8m
pounds ($12.6m) (1998: 6.7m pounds ($10.8m)) reflecting further progress through
clinical trials by XR9576 and XR5000, both of which entered Phase II trials
during the course of 1999. Continuing administrative costs fell to 2.0m pounds
($3.2m) (1998: 2.2m pounds ($3.5m)). Operating loss for the year was 10.9m
pounds ($17.6m) (1998: 14.6m pounds ($23.6m)). Operating loss for the six months
to 31 December 1999 was 4.7m pounds ($7.6m) (1998: 7.8m pounds ($12.5m)).

Disposals

The sale of the majority of the assets of Xenova Discovery Limited to TerraGen
Diversity Inc was completed in April 1999. The sale resulted in total realised
and unrealised gain on disposal of 3.0m pounds ($4.8m). Xenova received a total
of 1.0m pounds cash during 1999 plus 1 million preferred voting shares in
TerraGen Diversity Inc, valued at 1.5m pounds equivalent to 6% of the current
issued share capital. An interest bearing loan note of 1.5m pounds was also
issued to Xenova by TerraGen Diversity Inc. After 24 months the loan note can be
converted into TerraGen equity at the option of either party, and is
automatically convertible at the end of 36 months, which would be equivalent to
a further 6% of the current issued share capital. There is an anti dilution
provision under which if there is a subsequent financing at a lower price then
the conversion price of the loan note will be similarly adjusted. In line with
the issued draft guidance from the Institute of Chartered Accountants in England
and Wales, entitled `The determination of realised profits and distributable
profits in the context of the Companies Act 1985`, the total profit on the
disposal of the Xenova Discovery business disclosed in the Half year and
Quarterly announcements has now been analysed into that which has been realised
and that which is unrealised. Of the total profit of 3.0m pounds, the realised
element of 0.8m pounds has been included in the profit and loss for the year and
the unrealised profit of 2.2m pounds has been taken to the Statement of Total
Recognised Gains and Losses.

The sale of certain of the assets of MetaXen, a San Francisco-based subsidiary,
to Exelixis was completed in July 1999. The sale resulted in a loss on disposal
of 0.5m pounds ($0.8m). Xenova received total cash of 0.1m pounds ($0.2m).

Treasury

Xenova raised a total of 8.4m pounds net ($13.5m) from the placing and exercise
of warrants in the year to 31 December 1999. In July 1999 Xenova made a private
placing of 2,150,038 shares at 85p raising 1.8m pounds ($2.9m). The exercise of
warrants linked to an October 1998 placing and open offer raised 6.6m pounds
($10.6m) in the year.

Capital expenditure during the year was 0.1m pounds ($0.2m) (1998: 2.2m pounds
($3.5m). Proceeds from disposals of tangible fixed assets were 0.2m pounds
($0.3m) (1998: pounds nil).

Net interest of 0.5m pounds ($0.9m) was earned in the year (1998: 0.7m pounds
($1.1m)). Cash and liquid resources at year end were 10.1m pounds ($16.3m)
(1998: 11.4m pounds ($18.4m)).

Called up shares at 31 December 1999 were 54,627,506. Following completion of
the warrant exercise programme in January 2000, shares in issue rose to
54,706,537 as at 3rd March 2000.


The directors do not recommend the payment of a dividend (1998: nil).

Safe Harbor Statement under the US Private Securities Litigation Reform Act of
1995: Some or all of the statements in this document that relate to future
plans, expectations, events, performances and the like are forward-looking
statements, as defined in the US Private Securities Litigation Reform Act of
1995. Actual results of events could differ materially from those described in
the forward-looking statements due to a variety of factors, including those set
forth in the Company`s filings with the US Securities and Exchange Commission.


Xenova Group plc is a London Stock Exchange techMARK listed company.


Consolidated Profit and Loss Account

Unaudited
Unaudited Unaudited Six months Audited
Year ended Year ended ended Year ended
31 December 31 December 31 December 31 December
1999 1999 1999 1998
$000 (in thousands of pounds)

Turnover
Continuing operations 617 383 207 1,155
Discontinued operations 3,724 2,310 662 3,710
(Note 2) 4,341 2,693 869 4,865
Operating expenses 12,564 7,793 3,969 6,685
Research and development
Continuing operations 5,644 3,501 373 9,797
Discontinued operations 18,208 11,294 4,342 16,482

Administrative expenses
Continuing operations 3,227 2,002 1,214 2,176
Discontinued operations 521 323 26 843
3,748 2,325 1,240 3,019

Total operating expenses 21,956 13,619 5,582 19,501

Operating (loss)/ profit
Continuing operations (15,174) (9,412) (4,976) (7,706)
Discontinued operations (2,441) (1,514) 263 (6,930)
(17,615) (10,926) (4,713) (14,636)

Profit on sale of businesses
- Discontinued operations 436 271 49 --

Interest (net) 872 541 270 693

Loss on ordinary activities
before and after taxation,
retained loss for the period
attributable to members of
Xenova Group plc (16,307) (10,114) (4,394) (13,943)

Loss per share
(basic and diluted) (35c) (22p) (9p) (49p)
Shares used in computing net
Loss per share
(in thousands) 46,870 46,870 50,685 28,548


Statement of Total Recognised Gains and Losses

Unaudited
Unaudited Unaudited Six months Audited
Year ended Year ended ended Year ended
31 December 31 December 31 December 31 December
1999 1999 1999 1998
$000 (in thousands of pounds)

Loss attributable to members
of Xenova Group plc (16,307) (10,114) (4,394) (13,943)
Unrealised profit on
sale of business 3,494 2,167 -- --
Translation difference in
respect of overseas
subsidiary undertaking 11 7 145 (4)
Total recognised gains
and losses in the period
attributable to members of
Xenova Group plc (12,802) (7,940) (4,249) (13,947)

US Dollar amounts have been translated at the closing rate on 31 December 1999
(1.00 pounds: $1.6122) solely for informational purposes.


Consolidated Balance Sheet

Unaudited Unaudited Unaudited Audited
As at As at As at As at
31 31 30 31
December December June December
1999 1999 1999 1998
$000 (in thousands of pounds)
Fixed assets
Tangible fixed assets 529 328 1,586 3,636
Investments 2,418 1,500 1,500 --
2,947 1,828 3,086 3,636
Current assets
Debtors: due within one year 745 462 1,730 1,094
Debtors: due after one year 2,418 1,500 1,500 --
Investments 829 514 516 508
Cash at bank and in hand 15,424 9,567 4,494 10,884
19,416 12,043 8,240 12,486

Creditors: amounts
falling due within
one year (3,629) (2,251) (3,217) (4,266)
Net current assets 15,787 9,792 5,023 8,220

Total assets less current
liabilities 18,734 11,620 8,109 11,856

Creditors: amounts
falling due after
more than one year -- -- (347) (535)

Provisions for liabilities
and charges -- -- -- (140)

Total net assets 18,734 11,620 7,762 11,181

Capital and reserves
Called up share capital 8,807 5,463 4,339 4,300
Share premium 107,634 66,762 59,783 59,550
Other reserves 28,862 17,902 17,902 15,735
Profit and loss
account deficit (126,569) (78,507) (74,262) (68,404)
Shareholders funds -
equity interests(Note 3) 18,734 11,620 7,762 11,181

US Dollar amounts have been translated at the closing rate on 31 December 1999
(1.00 pound : $1.6122) solely for informational purposes.


Consolidated Cash Flow Statement

Unaudited
Unaudited Unaudited Six months Audited
Year ended Year ended ended Year ended
31 December 31 December 31 December 31 December
1999 1999 1999 1998
$000 (In thousands of pounds)

Net cash outflow from operating
activities (Note 4) (17,897) (11,101) (4,009) (12,597)

Returns on investments and
servicing of finance
Interest received 890 552 273 769
Interest element of finance
lease rental payments (56) (35) (4) (76)

Net cash inflow from returns
on investments and servicing
of finance 834 517 269 693

Capital expenditure and
financial investment
Purchase of tangible
fixed assets (164) (102) (39) (2,203)
Proceeds on disposal of tangible
fixed assets 355 220 -- 5

Net cash inflow/(outflow) from
capital expenditure and
financial investment 191 118 (39) (2,198)

Acquisitions and disposals
Net cash received from
businesses sold 1,511 937 770 --

Management of Liquid Resources
Purchase of Investments (1,669) (1,035) (516) (1,507)
Sale of Investments 1,659 1,029 519 2,002
(10) (6) 3 495

Net cash outflow before
financing (15,371) (9,535) (3,006) (13,607)

Financing
Issue of ordinary share capital
net of expenses 13,502 8,375 8,103 10,546
Repurchase of shares by
subsidiary undertaking (3) (2) (2) --
Capital element of finance
lease rental payments (256) (159) (21) (212)

Net cash inflow
from financing 13,243 8,214 8,080 10,334

(Decrease)/increase in cash
during the period (2,128) (1,321) 5,074 (3,273)


Reconciliation of Net Cash Flow to Movement in Net Funds

Unaudited
Unaudited Unaudited Six months Audited
Year ended Year ended ended Year ended
31 December 31 December 31 December 31 December
1999 1999 1999 1998
$000 (In thousands of pounds)

(Decrease)/increase in cash
in the period (2,128) (1,321) 5,074 (3,273)
Capital element of finance
lease payments 256 159 21 212
Change in liquid resources 10 6 (3) (495)
Change in net funds resulting
from cash flows (1,862) (1,156) 5,092 (3,556)

New finance leases -- -- -- --
Disposal of finance leases in
respect of discontinued
operations 1,088 675 578 (418)
Translation difference (31) (19) 13 3
Change in net funds (805) (500) 5,683 (3,971)

Net funds at 1 January/
1 July 17,059 10,581 4,398 14,552

Net funds at 1 December 16,254 10,081 10,081 10,581

US Dollar amounts have been translated at the closing rate on 31 December 1999
(1.00 pound: $1.6122) solely for informational purposes.


CONTACT: UK, David A Oxlade, Chief Executive Officer, Daniel Abrams,
Group Finance Director, Hilary Reid Evans, Corporate
Communications, all of Xenova Group plc, [phone]; or
David Yates, Sarah Mehanna, both of Financial Dynamics,
[phone]; or US, Joy E. Bessenger, Investors,
Tony Ho Loke, Media, 1-212-696-4455, both of Noonan - Russo
Communications, all for Xenova Group plc.

SOURCE Xenova Group plc

[Makkiavelli]

Hallo Leute,
Xenova ist nachbörslich auf 9,6$ gestiegen.
Nachzulesen unter www.nasdaq.com.

mfg

[oberfuchs]

Hallo
XENOVA hat ein neues Medikament in der Pipeline.

Gruß oberfuchs

[Stock Rave]

Hey Oberfuchs,
wo hast Du denn das gelesen?

Gruß
Stock Rave

[kfuchs]

Hallo ihr Füchse,

kann mir mal einer der Unterschied (auch im Preis) zwischen den beiden

890281 XGP XENOVA GRP PLC / D
890282 XNV XENOVA GRP PLC LS-,10 ADR / D

erklären?
Laßt einen Fuchs nicht dumm sterben

Gruß
KFuchs

[PeteInvests]

Hi StockRave,
mit dem neuen Medikament meint der Kollege oberfuchs sicher
XR 9576. Geht jetzt in Phase 3, also die letzte Phase vor
der Vermarktung.
XR 9576 wird in der Krebstherapie eingesetzt. Es ist eigentlich
nicht selbst ein Anti-Krebsmittel, sondern sorgt dafür, daß
Krebsmittel wirken können. Tumore entwickeln nämlich schnell
Resistenzen gegen Krebsmittel. Und XR 9576 schafft es, diese
Resistenzen nicht auftreten zu lassen.

kfuchs,
der Unterschied liegt darin, daß die 890281 die "richtige" Aktie
ist, wogegen in USA sog. "American Depository Receipts" gehandelt
werden, also aus der Aktie abgeleitete Scheine.
Kauf Dir die 890281. Kurse bewegen sich auf unterschiedlichem Niveau,
aber parallel.

Viel Erfolg, PI

[Stock Rave]

Hi PeteInvests,

danke für die Antwort. Dann dauert es also noch so 6 Monate, bis mit konkreten Ergebnissen zu rechnen ist, oder?

Gruß
Stock Rave

[Stock Rave]

Hi PeteInvests,

danke für die Antwort. Dann dauert es also noch so 6 Monate, bis mit konkreten Ergebnissen zu rechnen ist, oder?

Gruß
Stock Rave